Opna Bio LLC
Opna Bio is a clinical-stage biopharmaceutical company focused on discovering and developing novel oncology therapeutics. The company targets multiple drivers of cancer with a diversified pipeline of clinical and preclinical programs, including innovative programs targeting FMRP, BET proteins, EP300/CBP, and others. With a proven track record of advancing FDA-approved drugs, Opna aims to improve cancer treatment through scientific rigor, safety by design, and strategic collaborations.
Industries
Nr. of Employees
small (1-50)
Patents
Compounds and methods for EP300 or CBP modulation and indications therefor
US-11446287-B2
View Details
Compounds and methods for EP300 or CBP modulation and indications therefor
US-11446287-B2
View DetailsProducts
OPN-6602
Orally active small-molecule dual inhibitor of EP300 and CBP developed as an epigenetic modulator for multiple myeloma; demonstrated preclinical single-agent tumor growth inhibition and synergistic activity in combination studies.
OPN-2853
Differentiated BET bromodomain inhibitor being developed for myelofibrosis; tested in combination with a JAK inhibitor in investigator-led trials and associated with clinical evidence of spleen size reduction.
FMRP-targeted discovery program
Discovery-stage program targeting the fragile-X multifunctional RNA-binding protein (FMRP) to modulate tumor immune evasion and enhance anti-tumor immunity.
OPN-7486
Orally dosed small-molecule dual inhibitor of CSF1R and TRK aimed at inhibiting tumor-associated macrophage recruitment to enhance anti-tumor immunity; positioned for Phase 2 development.
OPN-9840
Oral, non-covalent pan-TEAD inhibitor showing single-agent efficacy in preclinical malignant mesothelioma and activity in melanoma models; planned for IND-enabling development.
OPN-9627
Orally available small-molecule CD73 inhibitor designed to block adenosine-mediated immunosuppression in the tumor microenvironment; advanced toward IND-enabling studies.
OPN-6602
Orally active small-molecule dual inhibitor of EP300 and CBP developed as an epigenetic modulator for multiple myeloma; demonstrated preclinical single-agent tumor growth inhibition and synergistic activity in combination studies.
OPN-2853
Differentiated BET bromodomain inhibitor being developed for myelofibrosis; tested in combination with a JAK inhibitor in investigator-led trials and associated with clinical evidence of spleen size reduction.
FMRP-targeted discovery program
Discovery-stage program targeting the fragile-X multifunctional RNA-binding protein (FMRP) to modulate tumor immune evasion and enhance anti-tumor immunity.
OPN-7486
Orally dosed small-molecule dual inhibitor of CSF1R and TRK aimed at inhibiting tumor-associated macrophage recruitment to enhance anti-tumor immunity; positioned for Phase 2 development.
OPN-9840
Oral, non-covalent pan-TEAD inhibitor showing single-agent efficacy in preclinical malignant mesothelioma and activity in melanoma models; planned for IND-enabling development.
OPN-9627
Orally available small-molecule CD73 inhibitor designed to block adenosine-mediated immunosuppression in the tumor microenvironment; advanced toward IND-enabling studies.
Services
Conduct and sponsor of Phase 1 and Phase 2 clinical trials, including dose-escalation/dose-expansion and combination studies in hematologic malignancies and other oncology indications.
Evaluation and potential provision of investigational agents outside clinical trials under defined medical and regulatory criteria.
Strategic collaborations, licensing and co-development arrangements to advance preclinical and clinical-stage oncology programs.
Conduct and sponsor of Phase 1 and Phase 2 clinical trials, including dose-escalation/dose-expansion and combination studies in hematologic malignancies and other oncology indications.
Evaluation and potential provision of investigational agents outside clinical trials under defined medical and regulatory criteria.
Strategic collaborations, licensing and co-development arrangements to advance preclinical and clinical-stage oncology programs.
Expertise Areas
- Oncology drug discovery
- Epigenetic modulator development
- Preclinical tumor pharmacology
- Early-stage clinical trial management (Phase 1/2)
Key Technologies
- Orally bioavailable small-molecule inhibitors
- Bromodomain inhibition (BET, EP300/CBP)
- TEAD inhibition
- CSF1R/TRK dual inhibition
News & Updates
Opna Bio announced that the FDA has granted orphan drug designation to OPN-6602 for the treatment of multiple myeloma. OPN-6602 is in a Phase 1 clinical trial for relapsed/refractory multiple myeloma.
Preclinical data with OPN-6602 in multiple myeloma shows 100% tumor regression in combination treatment studies.
Opna Bio raised $38 million in Series A financing to develop novel oncology therapeutics targeting FMRP, BET proteins, CSF1R, and other cancer drivers.
Opna Bio announced that the FDA has granted orphan drug designation to OPN-6602 for the treatment of multiple myeloma. OPN-6602 is in a Phase 1 clinical trial for relapsed/refractory multiple myeloma.
Preclinical data with OPN-6602 in multiple myeloma shows 100% tumor regression in combination treatment studies.
Opna Bio raised $38 million in Series A financing to develop novel oncology therapeutics targeting FMRP, BET proteins, CSF1R, and other cancer drivers.